AMRI and Saneca Pharmaceuticals formed a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients, (APIs). The collaboration combines Saneca’s strength in extracting opiates from plant biomass and their expertise in developing and manufacturing controlled substance APIs with AMRI’s U.S. assets and their ability to tech transfer processes into these facilities. The collaboration will also capitalize on AMRI’s s...